Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Torokbalint – page 83

1 123 clinical trials in Torokbalint, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Torokbalint at a glance
1 123
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 123 trials in Torokbalint

Open in trial search

Hidradenitis

Not recruiting

Study on Upadacitinib for Adults and Adolescents with Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Safety and Effects of Favezelimab and Pembrolizumab for Patients with Blood Cancers

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Chronic sinusitis

Not recruiting

Study on the Effectiveness and Safety of LYR-210 and Dexamethasone for Treating Chronic Sinusitis in Adults Without Nasal Polyps

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Lyra Therapeutics Inc.

Rheumatoid arthritis

Not recruiting

Study on Nipocalimab and Certolizumab for Patients with Active Rheumatoid Arthritis After Advanced Therapy

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:Janssen - Cilag International

Dry eye+1

Not recruiting

Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Graves' disease

Not recruiting

Study on the Effects of Satralizumab for Patients with Moderate-to-Severe Thyroid Eye Disease

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing MK-7684A and Pembrolizumab for Patients with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative

Not recruiting

Study on Upadacitinib for Children with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study on Venetoclax, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Torokbalint

What the registry says about research in the country

01 Lung Cancer Research

Extensive clinical trials focusing on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), evaluating innovative combination therapies and immunotherapy approaches.

  • Advanced NSCLC Treatments
  • Stage III-IV Cancer Therapies
  • Immunotherapy Combinations

Multiple studies investigating targeted therapies for various stages of lung cancer, particularly focusing on patients with specific genetic markers and PD-L1 expression levels.

02 Respiratory Conditions

Research initiatives addressing chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), testing new therapeutic approaches.

  • Uncontrolled Asthma Management
  • COPD Treatment Optimization
  • Cystic Fibrosis Therapies

Studies evaluating novel medications and combination therapies to improve patient outcomes in chronic respiratory conditions.

03 Innovative Therapeutics

Cutting-edge research examining novel drug combinations and treatment approaches, including targeted therapies and immunotherapy agents.

  • Combination Immunotherapies
  • Targeted Molecular Therapies
  • Maintenance Treatment Strategies

Focus on developing personalized treatment approaches based on specific biomarkers and genetic profiles.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.